Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2026-A00478-43 | Other Identifier | ID-RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
ECUM-RUN is a randomized, double-blind, placebo-controlled phase 3 trial evaluating whether a 30-day oral supplementation with curcumin, ginger, and piperine (9-5-1 formulation) reduces exercise-induced joint pain and inflammatory markers in 82 ultra-trail runners competing in the Diagonale des Fous (175 km). The primary endpoint is the change in knee pain (VAS score) between end of supplementation and race finish, compared between intervention and placebo groups.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 9-5-1 | Experimental |
| |
| Control | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 9-5-1 | Dietary Supplement | The investigational intervention is an oral food-supplement capsule combining curcumin, ginger, and piperine in a proprietary "9-5-1" ratio (curcuma extract : ginger extract : black pepper/piperine extract), administered as 4 capsules per day for 30 consecutive days prior to the race. |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Knee Pain Intensity from End of Supplementation to Race Finish (Visual Analog Scale) | Knee pain is self-assessed using a Visual Analog Scale (VAS, 0-10 cm) at the end of the 30-day supplementation period (T1, day before the race) and immediately at race finish or withdrawal (T2). The primary outcome is the within-participant change in VAS score (T2 minus T1), compared between the curcumin-ginger-piperine (9-5-1) group and the placebo group. | From Day 30 (T1, end of the 30-day supplementation period) to race finish or withdrawal (T2) - up to approximately 60 hours later, corresponding to the maximum allowed race duration. |
| Measure | Description | Time Frame |
|---|---|---|
| Kinetics of Joint Pain Across the Study Period (Ankles, Knees, Hips) | Pain intensity at the ankles, knees, and hips is self-assessed using a Visual Analog Scale (VAS, 0-10 cm) at each of the four measurement time points. Between-group differences (intervention vs. placebo) in the T2-T1 change are compared, and a mixed linear model is used to describe the overall pain trajectory from T0 to T3, accounting for repeated within-participant measures. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Nicolas BOUSCAREN, Dr | Contact | +33262353530 | Nicolas.BOUSCAREN@chu-reunion.fr |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Dietary Supplement | Capsule excipients are maltodextrin and hydroxypropylmethylcellulose (HPMC), allowing an identical-appearing placebo for double-blind conditions. |
|
| (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Change in Joint Range of Motion (Ankles, Knees, Hips) | Range of motion for each joint movement (in degrees) is measured by goniometry, separately for each joint and side, at each of the four time points. Between-group differences in the T2-T1 change in range of motion are compared for each joint tested. | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Change in circulating pro-inflammatory and anti-inflammatory cytokines (pg/mL) | Venous blood samples are collected at each study visit to measure serum IL-1β, IL-6, IL-8, IL-1ra and IL-10 and TNF-α concentrations. Between-group differences in the T2-T1 change are compared for each cytokine, and mixed linear models describe their kinetics across T0-T3. | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Change in Inflammatory biomarkers (ng/mL) | Venous blood samples are collected to measure serum calprotectin, resistin, and leptin concentrations. Between-group differences in the T2-T1 change are compared for each biomarker, and mixed linear models describe their kinetics across T0-T3. | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Change in serum enzyme activity (U/L) | Venous blood samples are collected to measure serum creatine kinase (CK), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Between-group differences in the T2-T1 change are compared for each enzyme, and mixed linear models describe their kinetics across T0-T3. | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Oxidative stress and adiponectin (µmol/L) | Venous blood samples are collected to measure serum malondialdehyde (MDA) and adiponectin. Between-group differences in the T2-T1 change are compared for each enzyme, and mixed linear models describe their kinetics across T0-T3. | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Changein serum creatinine (µmol/L) | Venous blood samples are collected to measure serum creatinine. Between-group differences in the T2-T1 change are compared for each enzyme, and mixed linear models describe their kinetics across T0-T3. | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Change in blood urea (mmol/L) | Venous blood samples are collected to measure in blood urea. Between-group differences in the T2-T1 change are compared for each enzyme, and mixed linear models describe their kinetics across T0-T3. | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Change in coagulation parameters | Venous blood samples are collected to assess prothrombin time (PT, %) and international normalized ratio (INR). Between-group differences in the T2-T1 change are compared for each parameter, and mixed linear models describe their kinetics across T0-T3 | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Clinical tolerance | Clinical tolerance is assessed at each study visit by recording digestive symptoms, allergic reactions, and other adverse events. | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| Biological safety laboratory parameters | Biological safety is assessed using routine laboratory parameters evaluating liver function, renal function, and coagulation throughout the study. | Baseline (T0, before supplementation) to Day 2 post-race or post-withdrawal (T3) |
| ID | Term |
|---|---|
| D018771 | Arthralgia |
| ID | Term |
|---|---|
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D010146 | Pain |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided